A Low-Molecular-Weight Compound K7174 Represses Hepcidin: Possible Therapeutic Strategy against Anemia of Chronic Disease

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Fujiwara, Tohru ^a   Ikeda, Takashi ^a   Nagasaka, Yuki ^a   Okitsu, Yoko ^a   Katsuoka, Yuna ^a   Fukuhara, Noriko ^a   Onishi, Yasushi ^a   Ishizawa, Kenichi ^a,b   Ichinohasama, Ryo ^a   Tomosugi, Naohisa ^c   Harigae, Hideo ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c Medical Research Institute Kanazawa Medical College   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BONE MORPHOGENETIC PROTEIN 4; CCAAT ENHANCER BINDING PROTEIN BETA; GROWTH DIFFERENTIATION FACTOR 15; HEPCIDIN; K 7174; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANISOLE DERIVATIVE; AZEPINE DERIVATIVE;

ANEMIA; ANEMIA OF CHRONIC DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GDF15 GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; HAMP GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MICROARRAY ANALYSIS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CHRONIC DISEASE; GENE REGULATORY NETWORK; GENETICS; HEMATOMA; HEPG2 CELL LINE; INSTITUTE FOR CANCER RESEARCH MOUSE; K562 CELL LINE; LIVER; METABOLISM; PROMOTER REGION; TUMOR CELL LINE;

ANEMIA; ANIMALS; ANISOLES; AZEPINES; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE, TUMOR; CHRONIC DISEASE; DOWN-REGULATION; GENE REGULATORY NETWORKS; GROWTH DIFFERENTIATION FACTOR 15; HEMATOMA; HEP G2 CELLS; HEPCIDINS; HUMANS; K562 CELLS; LIVER; MICE; MICE, INBRED ICR; PROMOTER REGIONS, GENETIC; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84884690739     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075568     Document Type: Article

References (30)

1. Ganz T, Nemeth E, (2012) Hepcidin and iron homeostasis. Biochim Biophys Acta 1823: 1434-1443. doi:10.1016/j.bbamcr.2012.01.014. PubMed: 22306005.
2. Finberg KE, (2013) Regulation of systemic iron homeostasis. Curr Opin Hematol 20: 208-214. doi:10.1097/MOH.0b013e32835f5a47. PubMed: 23426198.
3. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093. doi:10.1126/science.1104742. PubMed: 15514116.
4. Sun CC, Vaja V, Babitt JL, Lin HY, (2012) Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 87: 392-400. doi:10.1002/ajh.23110. PubMed: 22290531.
5. Weiss G, Goodnough LT, (2005) Anemia of chronic disease. N Engl J Med 352: 1011-1023. doi:10.1056/NEJMra041809. PubMed: 15758012.
6. Andrews NC, (2004) Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 113: 1251-1253. doi:10.1172/JCI21441. PubMed: 15124013.
7. Ganz T, (2003) Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102: 783-788. doi:10.1182/blood-2003-03-0672. PubMed: 12663437.
8. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, et al. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113: 1271-1276. doi:10.1172/JCI200420945. PubMed: 15124018.
9. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, et al.; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators (2010) Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363: 1146-1155 doi:10.1056/NEJMoa1005109. PubMed: 20843249.
10. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, et al.; American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee; Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR, American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee (2010) American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116: 4045-4059. doi:10.1182/blood-2010-08-300541. PubMed: 20974674. doi:10.1182/blood-2010-08-300541 PubMed: 20974674.
11. Umetani M, Nakao H, Doi T, Iwasaki A, Ohtaka M, et al. (2000) A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA. Biochem Biophys Res Commun 272: 370-374. doi:10.1006/bbrc.2000.2784. PubMed: 10833420.
12. Imagawa S, Nakano Y, Obara N, Suzuki N, Doi T, et al. (2003) A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J 17: 1742-1754. PubMed: 12958195.
13. Fujiwara T, Alqadi YW, Okitsu Y, Fukuhara N, Onishi Y, et al. (2013) Role of transcriptional corepressor ETO2 in erythroid cells. Exp Hematol 41: 303-315. doi:10.1016/j.exphem.2012.10.015. PubMed: 23127762.
14. Fujiwara T, O'Geen H, Keles S, Blahnik K, Linnemann AK, et al. (2009) Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy. Mol Cell 36: 667-681. doi:10.1016/j.molcel.2009.11.001. PubMed: 19941826.
15. Fujiwara T, Yokoyama H, Okitsu Y, Kamata M, Fukuhara N, et al. (2012) Gene expression profiling identifies HOXB4 as a direct downstream target of GATA-2 in human CD34+ hematopoietic cells. PLOS ONE 7: e40959. doi:10.1371/journal.pone.0040959. PubMed: 23028422.
16. Morgenstern JP, Land H, (1990) Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18: 3587-3596. doi:10.1093/nar/18.12.3587. PubMed: 2194165.
17. Hattori A, Tomosugi N, Tatsumi Y, Suzuki A, Hayashi K, et al. (2012) Identification of a novel mutation in the HAMP gene that causes non-detectable hepcidin molecules in a Japanese male patient with juvenile hemochromatosis. Blood Cells Mol Dis 48: 179-182. doi:10.1016/j.bcmd.2012.01.002. PubMed: 22297252.
18. Island ML, Fatih N, Leroyer P, Brissot P, L'Oreal O, (2011) GATA-4 transcription factor regulates hepatic hepcidin expression. Biochem J 437: 477-482. doi:10.1042/BJ20110225. PubMed: 21609320.
19. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, et al. (2007) High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13: 1096-1101. doi:10.1038/nm1629. PubMed: 17721544.
20. Lee SH, Krisanapun C, Baek SJ, (2010) NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta, C/EBPbeta and ATF3. Carcinogenesis 31: 719-728. doi:10.1093/carcin/bgq016. PubMed: 20110283.
21. Shimizu S, Kadowaki M, Yoshioka H, Kambe A, Watanabe T, et al. (2013) Proteasome inhibitor MG132 induces NAG-1/GDF15 expression through the p38 MAPK pathway in glioblastoma cells. Biochem Biophys Res Commun 430: 1277-1282. doi:10.1016/j.bbrc.2012.11.137. PubMed: 23261467.
22. Takano Y, Hiramatsu N, Okamura M, Hayakawa K, Shimada T, et al. (2007) Suppression of cytokine response by GATA inhibitor K-7174 via unfolded protein response. Biochem Biophys Res Commun 360: 470-475. doi:10.1016/j.bbrc.2007.06.082. PubMed: 17604001.
23. Shimada T, Hiramatsu N, Okamura M, Hayakawa K, Kasai A, et al. (2007) Unexpected blockade of adipocyte differentiation by K-7174: implication for endoplasmic reticulum stress. Biochem Biophys Res Commun 363: 355-360. doi:10.1016/j.bbrc.2007.08.167. PubMed: 17869220.
24. Hayakawa K, Nakajima S, Hiramatsu N, Okamura M, Huang T, et al. (2010) ER stress depresses NF-kappaB activation in mesangial cells through preferential induction of C/EBP beta. J Am Soc Nephrol 21: 73-81. doi:10.1681/ASN.2009040432. PubMed: 19875812.
25. Zhang AS, Yang F, Wang J, Tsukamoto H, Enns CA, (2009) Hemojuvelin-neogenin interaction is required for bone morphogenic protein-4-induced hepcidin expression. J Biol Chem 284: 22580-22589. doi:10.1074/jbc.M109.027318. PubMed: 19564337.
26. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, et al. (2006) Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38: 531-539. doi:10.1038/ng1777. PubMed: 16604073.
27. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, et al. (2007) Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 117: 1933-1939. doi:10.1172/JCI31342. PubMed: 17607365.
28. Theurl I, Schroll A, Sonnweber T, Nairz M, Theurl M, et al. (2011) Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 118: 4977-4984. doi:10.1182/blood-2011-03-345066. PubMed: 21730356.
29. Steinbicker AU, Sachidanandan C, Vonner AJ, Yusuf RZ, Deng DY, et al. (2011) Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 117: 4915-4923. doi:10.1182/blood-2010-10-313064. PubMed: 21393479.
30. Nakano Y, Imagawa S, Matsumoto K, Stockmann C, Obara N, et al. (2004) Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood 104: 4300-4307. doi:10.1182/blood-2004-04-1631. PubMed: 15328158.